Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts.

Hennessey PT, Ochs MF, Mydlarz WW, Hsueh W, Cope L, Yu W, Califano JA.

PLoS One. 2011;6(5):e20584. doi: 10.1371/journal.pone.0020584. Epub 2011 May 26.

2.

MAGEB2 is activated by promoter demethylation in head and neck squamous cell carcinoma.

Pattani KM, Soudry E, Glazer CA, Ochs MF, Wang H, Schussel J, Sun W, Hennessey P, Mydlarz W, Loyo M, Demokan S, Smith IM, Califano JA.

PLoS One. 2012;7(9):e45534. doi: 10.1371/journal.pone.0045534. Epub 2012 Sep 24.

3.

Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma.

Chaisaingmongkol J, Popanda O, Warta R, Dyckhoff G, Herpel E, Geiselhart L, Claus R, Lasitschka F, Campos B, Oakes CC, Bermejo JL, Herold-Mende C, Plass C, Schmezer P.

Oncogene. 2012 Dec 6;31(49):5108-16. doi: 10.1038/onc.2011.660. Epub 2012 Jan 30.

PMID:
22286769
4.

Validation of nucleolar protein 4 as a novel methylated tumor suppressor gene in head and neck cancer.

Demokan S, Chuang AY, Pattani KM, Sidransky D, Koch W, Califano JA.

Oncol Rep. 2014 Feb;31(2):1014-20. doi: 10.3892/or.2013.2927. Epub 2013 Dec 16.

5.

Differential methylation status of tumor-associated genes in head and neck squamous carcinoma: incidence and potential implications.

Maruya S, Issa JP, Weber RS, Rosenthal DI, Haviland JC, Lotan R, El-Naggar AK.

Clin Cancer Res. 2004 Jun 1;10(11):3825-30.

6.

[Aberrant promoter hypermethylation of tazarotine-induced gene 1 (TIG1) in head and neck cancer].

Tokumaru Y, Yahata Y, Fujii M.

Nihon Jibiinkoka Gakkai Kaiho. 2005 Dec;108(12):1152-7. Japanese.

PMID:
16440812
7.

Tumor suppressor activity and inactivation of galanin receptor type 2 by aberrant promoter methylation in head and neck cancer.

Misawa Y, Misawa K, Kanazawa T, Uehara T, Endo S, Mochizuki D, Yamatodani T, Carey TE, Mineta H.

Cancer. 2014 Jan 15;120(2):205-13. doi: 10.1002/cncr.28411. Epub 2013 Oct 10.

8.

Gene promoter-associated CpG island hypermethylation in squamous cell carcinoma of the tongue.

Bhat S, Kabekkodu SP, Jayaprakash C, Radhakrishnan R, Ray S, Satyamoorthy K.

Virchows Arch. 2017 Apr;470(4):445-454. doi: 10.1007/s00428-017-2094-2. Epub 2017 Mar 2.

PMID:
28255813
9.

Identification of guanine nucleotide-binding protein γ-7 as an epigenetically silenced gene in head and neck cancer by gene expression profiling.

Demokan S, Chuang AY, Chang X, Khan T, Smith IM, Pattani KM, Dasgupta S, Begum S, Khan Z, Liegeois NJ, Westra WH, Sidransky D, Koch W, Califano JA.

Int J Oncol. 2013 Apr;42(4):1427-36. doi: 10.3892/ijo.2013.1808. Epub 2013 Feb 6.

10.

Epigenetic inactivation of RASSF1A in head and neck cancer.

Dong SM, Sun DI, Benoit NE, Kuzmin I, Lerman MI, Sidransky D.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3635-40.

11.

Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.

Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH.

Oncol Rep. 2009 Dec;22(6):1519-26.

PMID:
19885608
12.

Genetic and epigenetic somatic alterations in head and neck squamous cell carcinomas are globally coordinated but not locally targeted.

Poage GM, Christensen BC, Houseman EA, McClean MD, Wiencke JK, Posner MR, Clark JR, Nelson HH, Marsit CJ, Kelsey KT.

PLoS One. 2010 Mar 11;5(3):e9651. doi: 10.1371/journal.pone.0009651.

13.

Key tumor suppressor genes inactivated by "greater promoter" methylation and somatic mutations in head and neck cancer.

Guerrero-Preston R, Michailidi C, Marchionni L, Pickering CR, Frederick MJ, Myers JN, Yegnasubramanian S, Hadar T, Noordhuis MG, Zizkova V, Fertig E, Agrawal N, Westra W, Koch W, Califano J, Velculescu VE, Sidransky D.

Epigenetics. 2014 Jul;9(7):1031-46. doi: 10.4161/epi.29025. Epub 2014 May 1.

14.

Analysis of DNA methylation and gene expression in radiation-resistant head and neck tumors.

Chen X, Liu L, Mims J, Punska EC, Williams KE, Zhao W, Arcaro KF, Tsang AW, Zhou X, Furdui CM.

Epigenetics. 2015;10(6):545-61. doi: 10.1080/15592294.2015.1048953.

15.

Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC).

Smiraglia DJ, Smith LT, Lang JC, Rush LJ, Dai Z, Schuller DE, Plass C.

J Med Genet. 2003 Jan;40(1):25-33.

16.

Promoter methylation in head and neck tumorigenesis.

Stephen JK, Chen KM, Havard S, Harris G, Worsham MJ.

Methods Mol Biol. 2012;863:187-206. doi: 10.1007/978-1-61779-612-8_11.

17.

Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.

Harris M, Wang XG, Jiang Z, Goldberg GL, Casadevall A, Dadachova E.

Head Neck Oncol. 2011 Feb 12;3(1):9. doi: 10.1186/1758-3284-3-9.

18.

Novel approaches to global mining of aberrantly methylated promoter sites in squamous head and neck cancer.

Worsham MJ, Chen KM, Stephen JK, Havard S, Benninger MS.

Otolaryngol Head Neck Surg. 2010 Jul;143(1):116-21, 121.e1-19. doi: 10.1016/j.otohns.2010.02.015.

19.

Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.

Heo DS, Snyderman C, Gollin SM, Pan S, Walker E, Deka R, Barnes EL, Johnson JT, Herberman RB, Whiteside TL.

Cancer Res. 1989 Sep 15;49(18):5167-75.

20.

Deleted in colorectal cancer is a putative conditional tumor-suppressor gene inactivated by promoter hypermethylation in head and neck squamous cell carcinoma.

Carvalho AL, Chuang A, Jiang WW, Lee J, Begum S, Poeta L, Zhao M, Jerónimo C, Henrique R, Nayak CS, Park HL, Brait MR, Liu C, Zhou S, Koch W, Fazio VM, Ratovitski E, Trink B, Westra W, Sidransky D, Moon CS, Califano JA.

Cancer Res. 2006 Oct 1;66(19):9401-7.

Supplemental Content

Support Center